Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker VRTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 11,866 | $531.53 | $6.3M Sale | Form 4 ↗ |
| Jul 2, 2026 | Ourania Tatsis EVP, Chief Reg. & Quality Off. | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,500 | $524.99 | $787.5K Sale | Form 4 ↗ |
| Jul 2, 2026 | Duncan McKechnie EVP, Chief Commercial Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,541 | $519.00 | $799.8K Sale | Form 4 ↗ |
| Jul 1, 2026 | Joy Liu EVP and Chief Legal Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 828 | $502.71 | $416.2K Sale | Form 4 ↗ |
| Jun 26, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 596 | $482.50 | $287.6K Sale | Form 4 ↗ |
| Jun 18, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,020 | $462.17 | $471.4K Sale | Form 4 ↗ |
| Jun 15, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 4,062 | $450.00 | $1.8M Sale | Form 4 ↗ |
| Jun 5, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,745 | $450.00 | $785.3K Sale | Form 4 ↗ |
| Jun 1, 2026 | Joy Liu EVP and Chief Legal Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 828 | $439.91 | $364.2K Sale | Form 4 ↗ |
| May 29, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,974 | $450.00 | $888.3K Sale | Form 4 ↗ |
| May 15, 2026 | Mark E. Bunnage EVP, Chief Scientific Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 33 | $453.45 | $15.0K Sale | Form 4 ↗ |
| May 15, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,354 | $453.45 | $614.0K Sale | Form 4 ↗ |
| May 12, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 6,988 | $450.00 | $3.1M Sale | Form 4 ↗ |
| May 4, 2026 | Sangeeta N. Bhatia Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 318 | $423.73 | $134.7K Sale | Form 4 ↗ |
| May 1, 2026 | Joy Liu EVP and Chief Legal Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,104 | $425.02 | $469.2K Sale | Form 4 ↗ |
| Apr 1, 2026 | Joy Liu EVP and Chief Legal Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 978 | $449.17 | $439.3K Sale | Form 4 ↗ |
| Mar 27, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,329 | $450.95 | $1.1M Sale | Form 4 ↗ |
| Mar 13, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,329 | $481.79 | $1.1M Sale | Form 4 ↗ |
| Mar 11, 2026 | Duncan McKechnie EVP, Chief Commercial Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,633 | $498.42 | $1.3M Sale | Form 4 ↗ |
| Mar 4, 2026 | Duncan McKechnie EVP, Chief Commercial Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,437 | $475.30 | $1.2M Sale | Form 4 ↗ |
| Mar 2, 2026 | Joy Liu EVP and Chief Legal Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 892 | $495.96 | $442.4K Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,725 | $496.95 | $857.2K Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 5,995 | $496.16 | $3.0M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 15,580 | $495.38 | $7.7M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 3,498 | $494.33 | $1.7M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,520 | $493.29 | $1.2M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 949 | $491.30 | $466.2K Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,725 | $490.54 | $1.3M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 460 | $489.32 | $225.1K Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 3,278 | $488.27 | $1.6M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,510 | $487.13 | $1.2M Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 240 | $482.84 | $115.9K Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 120 | $481.50 | $57.8K Sale | Form 4 ↗ |
| Feb 27, 2026 | Reshma Kewalramani CEO & President, Director | VRTX Vertex Pharmaceuticals Incorporated | Sale | 400 | $479.75 | $191.9K Sale | Form 4 ↗ |
| Feb 27, 2026 | Carmen Bozic EVP and CMO | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,329 | $480.31 | $1.1M Sale | Form 4 ↗ |
| Feb 26, 2026 | Kristen Ambrose SVP & Chief Accounting Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 357 | $483.36 | $172.6K Sale | Form 4 ↗ |
| Feb 25, 2026 | Ourania Tatsis EVP, Chief Reg. & Quality Off. | VRTX Vertex Pharmaceuticals Incorporated | Sale | 260 | $486.35 | $126.5K Sale | Form 4 ↗ |
| Feb 25, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,846 | $486.35 | $897.8K Sale | Form 4 ↗ |
| Feb 25, 2026 | Duncan McKechnie EVP, Chief Commercial Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,410 | $489.00 | $1.2M Sale | Form 4 ↗ |
| Feb 25, 2026 | Duncan McKechnie EVP, Chief Commercial Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 2,500 | $486.35 | $1.2M Sale | Form 4 ↗ |
| Feb 25, 2026 | Mark E. Bunnage EVP, Chief Scientific Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 620 | $486.35 | $301.5K Sale | Form 4 ↗ |
| Feb 25, 2026 | Jonathan Biller EVP and Chief Legal Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 945 | $486.35 | $459.6K Sale | Form 4 ↗ |
| Feb 25, 2026 | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | VRTX Vertex Pharmaceuticals Incorporated | Sale | 668 | $486.35 | $324.9K Sale | Form 4 ↗ |
| Feb 25, 2026 | Kristen Ambrose SVP & Chief Accounting Officer | VRTX Vertex Pharmaceuticals Incorporated | Sale | 223 | $486.35 | $108.5K Sale | Form 4 ↗ |
| Feb 19, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 4,237 | $471.43 | $2.0M Sale | Form 4 ↗ |
| Feb 19, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 11,712 | $470.54 | $5.5M Sale | Form 4 ↗ |
| Feb 19, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 7,241 | $469.61 | $3.4M Sale | Form 4 ↗ |
| Feb 19, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 19,662 | $468.57 | $9.2M Sale | Form 4 ↗ |
| Feb 19, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 10,263 | $467.75 | $4.8M Sale | Form 4 ↗ |
| Feb 19, 2026 | Amit Sachdev EVP Chief Patient & Ext Af Off | VRTX Vertex Pharmaceuticals Incorporated | Sale | 1,848 | $465.80 | $860.8K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances